Metastatic breast cancer research hub

FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: A pilot study for a randomized clinical trial (MONITOR-PILOT)

This study looks at different scans for people with advanced breast cancer. It compares standard CT scans with a special FDG-PET/CT scan to see which better shows how well treatment is working and if it helps people live longer and have a better quality of life.

A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)

This study looks at new drug combinations for advanced breast cancer that has spread. It focuses on a type of breast cancer called 'HER2-low'. Doctors want to see if these combinations are safe, how they work in the body, and if they can help shrink tumours.

Phase II Open Labeled Trial of Disulfiram with Copper in Metastatic Breast Cancer

This study is looking at a new treatment for advanced breast cancer using two existing medicines, disulfiram and copper. Researchers want to see if this combination can shrink the cancer or stop it from growing, and ultimately help people live longer and feel better.

A Study to assess the safety and potential use of GEH121224 (18F) Injection to visualise HER2-Receptor expression using PET imaging in patients with Metastatic Breast Cancer

This study looks at a new injection called GEH121224 (18F) to see if it can help doctors find breast cancer that has spread. It uses a special scan called a PET scan to see if cancer cells have a certain marker, called HER2, which can help guide treatment.

A randomized, double-blind, parallel-group, multicentre, phase II study to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo and fulvestrant (FaslodexTM) 500mg in combination with PD-0332991 (Palbociclib) as first line treatment for postmenopausal women with hormone receptor-positive metastatic breast cancer, who have completed at least 5 years of adjuvant endocrine therapy and remained disease free for more than 12 months following its completion or have de novo metastatic disease. "The FLIPPER Study"

This study, called "The FLIPPER Study," is looking at new treatments for women with breast cancer that has spread. It compares a standard drug (Faslodex) with a new combination of Faslodex and another drug (Palbociclib) to see if it works better at stopping the cancer from growing.

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

This study looks at adding a new drug, ipatasertib, to standard treatment for advanced breast cancer that hasn't responded well to initial therapy. It uses a blood test to identify patients who might benefit most from this additional treatment.

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

This study is testing a new drug, ST101, for people with advanced cancers like breast cancer, melanoma, and glioblastoma. It aims to see if the drug is safe, how much to give, and if it could help shrink tumors. It's for adults whose cancer hasn't responded to other treatments.

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

This study is testing a new medicine called EP0062 for advanced breast cancer. It aims to find the safest and most effective dose, both alone and with other standard treatments, for women whose cancer has specific features.

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

This study is looking at a new combination of treatments, Inavolisib and Phesgo, for HER2-positive breast cancer that has spread. We want to see if this new combination works better and is safe compared to Phesgo alone after initial treatment.

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

This study looks at a new drug, DB-1303/BNT323, for advanced breast cancer that's 'HER2-low' and hormone-positive. It compares the new drug to standard chemotherapy to see if it can stop the cancer from growing for longer.

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This study looks at a new drug, palazestrant, combined with standard treatment (ribociclib) for advanced breast cancer that is ER-positive and HER2-negative. It compares this new combination to the standard treatment alone to see if it works better and is safe for people who haven't had other treatments for their advanced cancer.

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

This study looks at a new combination of experimental drugs, disitamab vedotin and tucatinib, for advanced breast or stomach cancers that have a specific marker called HER2. It aims to see how safe and effective this treatment is, and what side effects it might cause.

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

This study is testing a new combination treatment for advanced breast cancer. It combines a drug called belzutifan with fulvestrant, comparing it to standard hormone therapy. The goal is to see if this new approach is effective and safe for people whose cancer has spread and is hormone-sensitive.

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

This study compares a new medicine called palazestrant with standard treatments for advanced breast cancer that has grown despite previous hormone therapy. It's for men and women whose cancer is ER-positive and HER2-negative.

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

This study looks at combining two drugs, palbociclib and avelumab, for a specific type of advanced breast cancer called triple negative. We want to find the safest dose and see how well it works, especially for cancers with a particular marker called AR.

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

This study is testing two new treatments, BNT323 and BNT327, for advanced breast cancer. It aims to find the safest and most effective dose when used together, and to see if this combination helps patients with different types of breast cancer.

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

This study is looking at new combinations of medicines for HER2-positive breast cancer that has spread. It aims to see how safe and effective these combinations are in patients whose advanced breast cancer has come back or spread.

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

This study compares two treatments for advanced breast cancer. It looks at lasofoxifene with abemaciclib versus fulvestrant with abemaciclib for ER+/HER2- breast cancer that has a specific gene change (ESR1 mutation) and has grown after previous treatment.

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

This study looks at a new drug, zongertinib, for different HER2+ cancers that have spread. Researchers want to find the best dose, alone and with other treatments, to see if it can shrink tumours.

Individualized everolimus therapy in metastatic breast cancer

This study looks at how different ways of taking Everolimus medicine affect quality of life for people with metastatic breast cancer. It compares taking the drug once a day versus in smaller doses throughout the day.

A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy on top of first line anti-HER2 targeted treatment of patients with Metastatic Breast Cancer TherO2-01S22 in HER2-positive breast cancer: TherO2-MBC Study

This study is testing a new drug, TherO2-01S22, for people with metastatic breast cancer that is HER2-positive. It aims to see how well it works and if it's safe when added to standard treatments. Researchers want to understand if it can shrink tumours.

A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negative metastatic breast cancer through an integrated liquid biopsy algorithm.

This study is for women with advanced hormone-positive, HER2-negative breast cancer that has spread. It aims to find the best second treatment by looking at changes in their blood. Researchers want to see which treatments work best to shrink cancer or stop it from growing for at least six months.

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

This study is testing a new drug called elacestrant with other breast cancer medicines. It's for people with a specific type of advanced breast cancer that has spread. The main goals are to see if these drug combinations are safe and if they can help shrink the cancer.

Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution

This study aims to understand how breast cancer changes over time, especially when it spreads. Researchers will take several small tissue samples and blood tests from different areas to see how the cancer evolves. This could help develop better treatments in the future.

Phase II trial of trastuzumab deruxtecan in first-line treatment HER2-positive locally advanced or metastatic breast cancer (MBC) patients considered resistant to trastuzumab + pertuzumab + taxane due to early relapse. “TRANSCENDER Study”

AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

The AURORA study aims to understand advanced breast cancer better. It collects tissue and blood samples from patients across Europe to find out why treatments work or don't. This research could help doctors find the best treatments for each patient in the future.